Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

Sponsor
AstraZeneca (Industry)
Overall Status
Completed
CT.gov ID
NCT00081380
Collaborator
(none)
710
94
30
7.6
0.3

Study Details

Study Description

Brief Summary

The purpose of this study is to determine whether quetiapine when used as adjunct to lithium or divalproex is safe and effective in the maintenance treatment of adult patients with Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment Phase and the Randomized treatment Phase.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Condition or Disease Intervention/Treatment Phase
  • Drug: Seroquel®, quetiapine fumarate (atypical antipsychotic)
  • Drug: lithium (mood stabilizer)
  • Drug: divalproex (mood stabilizer)
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Prevention
Official Title:
Multicenter, Randomized, Parallel-Group, Double-Blind, Phase 3 Comparison of the Efficacy & Safety of Quetiapine Fumarate to Placebo as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients (Abbreviated)
Study Start Date :
Mar 1, 2004
Actual Study Completion Date :
Sep 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Evaluate the efficacy of quetiapine versus placebo when used as adjunct therapy to mood stabilizer in increasing time to recurrence of a mood event. []

Secondary Outcome Measures

  1. Evaluate the efficacy of quetiapine versus placebo when used as a adjunct therapy to mod stabilizer in increasing time to recurrence of a manic event. []

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Open-Label

  • A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)

  • At least 1 manic, depressed, or mixed episode in the 2 years prior to the index episode.

  • Able to understand and comply with the requirements of the study.

Exclusion Criteria:

Open-Label

  • Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with medication within the past year.

  • Known intolerance or lack of response to quetiapine fumarate or to the assigned mood stabilizer, as judged by the investigator.

  • Previously randomized into this study or D1447C00126

Contacts and Locations

Locations

Site City State Country Postal Code
1 Research Site Birmingham Alabama United States
2 Research Site Scottsdale Arizona United States
3 Research Site Little Rock Arkansas United States
4 Research Site Anaheim California United States
5 Research Site Cerritos California United States
6 Research Site Chula Vista California United States
7 Research Site Culver City California United States
8 Research Site Garden Grove California United States
9 Research Site La Mesa California United States
10 Research Site Oceanside California United States
11 Research Site Orange California United States
12 Research Site Pico Rivera California United States
13 Research Site Riverside California United States
14 Research Site Rosemead California United States
15 Research Site San Diego California United States
16 Research Site San Francisco California United States
17 Research Site Santa Ana California United States
18 Research Site Farmington Connecticut United States
19 Research Site New Britain Connecticut United States
20 Research Site Jacksonville Florida United States
21 Research Site Miami Florida United States
22 Research Site Orlando Florida United States
23 Research Site West Palm Beach Florida United States
24 Research Site Winter Park Florida United States
25 Research Site Atlanta Georgia United States
26 Research Site Decatur Georgia United States
27 Research Site Marietta Georgia United States
28 Research Site Smyrna Georgia United States
29 Research Site Honolulu Hawaii United States
30 Research Site Chicago Illinois United States
31 Research Site Hoffman Estates Illinois United States
32 Research Site Joliet Illinois United States
33 Research Site Evansville Indiana United States
34 Research Site Greenwood Indiana United States
35 Research Site Indianapolis Indiana United States
36 Research Site Wichita Kansas United States
37 Research Site Florence Kentucky United States
38 Research Site Lake Charles Louisiana United States
39 Research Site New Orleans Louisiana United States
40 Research Site Shreveport Louisiana United States
41 Research Site Baltimore Maryland United States
42 Research Site Rockville Maryland United States
43 Research Site Pittsfield Massachusetts United States
44 Research Site New Baltimore Michigan United States
45 Research Site St. Louis Missouri United States
46 Research Site Clementon New Jersey United States
47 Research Site Moorestown New Jersey United States
48 Research Site West Caldwell New Jersey United States
49 Research Site Albuquerque New Mexico United States
50 Research Site Bronx New York United States
51 Research Site Brooklyn New York United States
52 Research Site New York New York United States
53 Research Site Butner North Carolina United States
54 Research Site Raleigh North Carolina United States
55 Research Site Beachwood Ohio United States
56 Research Site Cincinnati Ohio United States
57 Research Site Dayton Ohio United States
58 Research Site Medina Ohio United States
59 Research Site Oklahoma City Oklahoma United States
60 Research Site Tulsa Oklahoma United States
61 Research Site Eugene Oregon United States
62 Research Site Portland Oregon United States
63 Research Site Emmaus Pennsylvania United States
64 Research Site Moon Township Pennsylvania United States
65 Research Site Philadelphia Pennsylvania United States
66 Research Site Charleston South Carolina United States
67 Research Site Memphis Tennessee United States
68 Research Site Austin Texas United States
69 Research Site Dallas Texas United States
70 Research Site DeSoto Texas United States
71 Research Site Houston Texas United States
72 Research Site Irving Texas United States
73 Research Site San Antonio Texas United States
74 Research Site Wichita Falls Texas United States
75 Research Site Charlottesville Virginia United States
76 Research Site Falls Church Virginia United States
77 Research Site Richmond Virginia United States
78 Research Site Virginia Beach Virginia United States
79 Research Site Bellevue Washington United States
80 Research Site Kirkland Washington United States
81 Research Site Morgantown West Virginia United States
82 Research Site Edmonton Alberta Canada
83 Research Site Vancouver British Columbia Canada
84 Research Site Victoria British Columbia Canada
85 Research Site Winnipeg Manitoba Canada
86 Research Site Halifax Nova Scotia Canada
87 Research Site Hamilton Ontario Canada
88 Research Site Kingston Ontario Canada
89 Research Site Markham Ontario Canada
90 Research Site Mississauga Ontario Canada
91 Research Site Oshawa Ontario Canada
92 Research Site Toronto Ontario Canada
93 Research Site Montreal Quebec Canada
94 Research Site Quebec Canada

Sponsors and Collaborators

  • AstraZeneca

Investigators

  • Study Director: AstraZeneca Seroquel Medical Science Director, MD, AstraZeneca

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00081380
Other Study ID Numbers:
  • D1447C00127
First Posted:
Apr 19, 2004
Last Update Posted:
Dec 22, 2008
Last Verified:
Dec 1, 2008

Study Results

No Results Posted as of Dec 22, 2008